193 related articles for article (PubMed ID: 23532208)
1. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.
Tokito T; Shukuya T; Akamatsu H; Taira T; Ono A; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Yamamoto N
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1493-8. PubMed ID: 23532208
[TBL] [Abstract][Full Text] [Related]
2. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
Nørøxe DS; Wallerek S; Sørensen JB
Anticancer Res; 2013 Aug; 33(8):3275-8. PubMed ID: 23898091
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.
Tamiya M; Tamiya A; Nakao K; Asami K; Okishio K; Satomu M; Shiroyama T; Morishita N; Suzuki H; Sasada S; Okamoto N; Okishio K; Kawaguchi T; Kobayashi M; Atagi S; Hirashima T; Kawase I
Anticancer Res; 2012 Aug; 32(8):3553-7. PubMed ID: 22843945
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
8. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
12. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
[TBL] [Abstract][Full Text] [Related]
14. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
15. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
[TBL] [Abstract][Full Text] [Related]
16. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Kentepozidis N; Kotsakis A; Soultati A; Agelaki S; Christophylakis Ch; Agelidou M; Chelis L; Papakotoulas P; Vamvakas L; Zafiriou Z; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2013 Mar; 71(3):605-12. PubMed ID: 23338050
[TBL] [Abstract][Full Text] [Related]
18. [Anti-VEGF therapy for lung cancer].
Taira T; Yamamoto N
Nihon Rinsho; 2012 Dec; 70(12):2159-64. PubMed ID: 23259390
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
Akerley W; Boucher K; Rich N; Egbert L; Harker G; Bylund J; Van Duren T; Reddy C
Lung Cancer; 2013 Mar; 79(3):307-11. PubMed ID: 23273522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
